Clinical Trial Results:
High volume haemodiafiltration in treatment of severe sepsis -- impact on pharmacokinetics of doripenem and piperacillin tazobactam and inflammatory response.
Summary
|
|
EudraCT number |
2011-000644-16 |
Trial protocol |
EE |
Global end of trial date |
25 Jun 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Jan 2020
|
First version publication date |
02 Jan 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Dor1.0
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University of Tartu, Clinic of Anaesthesiology and Intensive Care
|
||
Sponsor organisation address |
L. Puusepa 8, Tartu, Estonia, 51014
|
||
Public contact |
Principal Investigator, University of Tartu, Clinic of Anaesthesiology and Intensive Care, kadri.tamme@kliinikum.ee
|
||
Scientific contact |
Principal Investigator, University of Tartu, Clinic of Anaesthesiology and Intensive Care, kadri.tamme@kliinikum.ee
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
29 Sep 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
25 Jun 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
25 Jun 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Describe the pharmacokinetics of doripenem and piperacillin-tazobactam during high volume haemofiltration.
|
||
Protection of trial subjects |
All patients were treated and monitored in intensive care.
Informed consent was obtained from the patient or legal representative prior to study inclusion.
All blood samples were drawn from indwelling arterial catheter.
Patients with known hypersensitivity to carbapenems, penicillins or other beta-lactams were excluded.
|
||
Background therapy |
All patients received high volume haemodiafiltration prescribed by the treating physician. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Sep 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Estonia: 19
|
||
Worldwide total number of subjects |
19
|
||
EEA total number of subjects |
19
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
10
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Pharmacokinetics of doripenem during HVHDF - 9 patients recruited from September 1, 2011 till August 31, 2012. Pharmacokinetics of piperacillin/tazobactam during HVHDF - 10 patients were recruited from September 1, 2012 till June 25, 2014. | ||||||
Pre-assignment
|
|||||||
Screening details |
Patients in severe sepsis or septic shock who were prescribed high volume haemodiafiltration were eligible. Of 36 prescreened patients, 19 were enrolled in the study. The reasons for exclusion were were absence of informed consent from next of kin, life expectancy of < 8 hours, and age <18 years. | ||||||
Period 1
|
|||||||
Period 1 title |
Overall trial (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Single arm | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Doripenem
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Powder for solution for injection/infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
A single dose of 500 mg of doripenem in 50 mL of 0.9% sodium chloride was administered in addition to the ongoing antibacterial therapy as a 1 hour intravenous infusion.
|
||||||
Investigational medicinal product name |
Piperacillin/tazobactam
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Powder for solution for injection/infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
A single dose of 4000 mg of piperacillin and 500 mg of tazobactam in 50 mL of 0.9% sodium chloride was administered in addition to the ongoing antibacterial therapy as a 30 minute intravenous infusion.
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Doripenem pharmacokinetics
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients who received doripenem
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Piperacillin/tazobactam pharmacokinetics
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients who received piperacillin/tazobactm
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Single arm
|
||
Reporting group description |
- | ||
Subject analysis set title |
Doripenem pharmacokinetics
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Patients who received doripenem
|
||
Subject analysis set title |
Piperacillin/tazobactam pharmacokinetics
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Patients who received piperacillin/tazobactm
|
|
|||||||||||||
End point title |
Pharmacokinetic parameter total body clearance | ||||||||||||
End point description |
Non-linear mixed effects modelling was used to estiamte the total body clearance of the study drug.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Blood samples were collected before and immediately after the end of study drug infusion, every half hour for 4 hours and then every hour till 8 hours after the study drug administration.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Non-linear mixed effects modelling | ||||||||||||
Statistical analysis description |
PK data were analysed by non-linear mixed effect modelling.
|
||||||||||||
Comparison groups |
Piperacillin/tazobactam pharmacokinetics v Doripenem pharmacokinetics
|
||||||||||||
Number of subjects included in analysis |
19
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [1] | ||||||||||||
P-value |
< 0.01 [2] | ||||||||||||
Method |
Mixed models analysis | ||||||||||||
Confidence interval |
|||||||||||||
Notes [1] - Non-linear mixed effects modelling. No comparisons between analysis groups were performed [2] - Covariates that reduced the objective function value (OFV) by at least 6.635 points (p<0.01) were considered statistically significant and included in the subsequent covariate analysis. |
|
|||||||||||||
End point title |
Pharmacokinetic parameter volume of distribution of central compartment | ||||||||||||
End point description |
Non-linear mixed effects modelling was used to estimate volume of distribution of central compartment.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Blood samples were collected before and immediately after the end of study drug infusion, every half hour for 4 hours and then every hour till 8 hours after the study drug administration.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Pharmacokinetic parameter volume of distribution of peripheral compartment | ||||||||||||
End point description |
Non-linear mixed effects modelling was used to estimate volume of distribution of peripheral compartment
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Blood samples were collected before and immediately after the end of study drug infusion, every half hour for 4 hours and then every hour till 8 hours after the study drug administration.
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All patients were monitored for adverse events for at least 7 days after study drug administration.
|
||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All patients were monitored for adverse events for at least 7 days after study drug administration. Monitoring included clinical evaluation for occurrence of allergic reactions and seizures, laboratory and vital parameters and microbiological cultures. Concomitant medications were recorded during the whole ICU stay.
|
||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||
Dictionary version |
15
|
||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||
Reporting group title |
Doripenem group
|
||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||
Reporting group title |
Piperacillin/tazobactam group
|
||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/25408310 http://www.ncbi.nlm.nih.gov/pubmed/26830215 http://www.ncbi.nlm.nih.gov/pubmed/26064875 |